ID

13749

Beschreibung

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01074047

Link

https://clinicaltrials.gov/show/NCT01074047

Stichworte

Versionen (1)
  1. 02.03.16 02.03.16 -
Rechteinhaber

CC BY-NC 3.0

Hochgeladen am

2. März 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Acute Myeloid Leukemia NCT01074047

Englisch

Eligibility Acute Myeloid Leukemia NCT01074047

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of one of the following
Beschreibung

ID.1

Datentyp

boolean

newly diagnosed de novo acute myeloid leukemia (aml)
Beschreibung

newly diagnosed de novo acute myeloid leukemia (aml)

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C1515568
aml secondary to myelodysplastic syndromes (mds)
Beschreibung

aml secondary to myelodysplastic syndromes (mds)

Datentyp

boolean

Alias
UMLS CUI [1]
C0280449
UMLS CUI [2]
C3463824
aml secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years
Beschreibung

aml secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years

Datentyp

boolean

Alias
UMLS CUI [1]
C0280449
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C2983796
bone marrow blasts >30%
Beschreibung

bone marrow blasts >30%

Datentyp

boolean

Alias
UMLS CUI [1]
C1982687
age ≥ 65 years
Beschreibung

age ≥ 65 years

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
easter cooperative oncology group (ecog) 0-2
Beschreibung

easter cooperative oncology group (ecog) 0-2

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous cytotoxic or biologic treatment for aml (except hydroxyurea)
Beschreibung

previous cytotoxic or biologic treatment for aml (except hydroxyurea)

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C1514463
UMLS CUI [2]
C0020402
previous treatment with azacitidine, decitabine or cytarabine
Beschreibung

previous treatment with azacitidine, decitabine or cytarabine

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0004475
UMLS CUI [1,2]
C1514463
UMLS CUI [2,1]
C0049065
UMLS CUI [2,2]
C1514463
UMLS CUI [3,1]
C0010711
UMLS CUI [3,2]
C1514463
prior use of targeted therapy agents (e.g., flt3 inhibitors, other kinase inhibitors)
Beschreibung

prior use of targeted therapy agents (e.g., flt3 inhibitors, other kinase inhibitors)

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2985566
UMLS CUI [1,2]
C1514463
aml french american british subtype (fab m3)
Beschreibung

aml french american british subtype (fab m3)

Datentyp

boolean

Alias
UMLS CUI [1]
C0023487
aml associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes
Beschreibung

aml associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0008625
prior bone marrow or stem cell transplantation
Beschreibung

prior bone marrow or stem cell transplantation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0005961
UMLS CUI [1,2]
C0332152
UMLS CUI [2,1]
C1504389
UMLS CUI [2,2]
C0332152
candidate for allogeneic bone marrow or stem cell transplant
Beschreibung

candidate for allogeneic bone marrow or stem cell transplant

Datentyp

boolean

Alias
UMLS CUI [1]
C0005961
UMLS CUI [2]
C1504389
diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, "in-situ" carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure)
Beschreibung

diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, "in-situ" carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure)

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
malignant hepatic tumors
Beschreibung

malignant hepatic tumors

Datentyp

boolean

Alias
UMLS CUI [1]
C0345904
uncontrolled systemic infection
Beschreibung

uncontrolled systemic infection

Datentyp

boolean

Alias
UMLS CUI [1]
C3646020
active viral infection with human immunodeficiency virus (hiv) or hepatitis type b or c
Beschreibung

active viral infection with human immunodeficiency virus (hiv) or hepatitis type b or c

Datentyp

boolean

Alias
UMLS CUI [1]
C0019682
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196
use of any experimental drug or therapy within 28 days prior to day 1
Beschreibung

use of any experimental drug or therapy within 28 days prior to day 1

Datentyp

boolean

Alias
UMLS CUI [1]
C0304229
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Acute Myeloid Leukemia NCT01074047

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
diagnosis of one of the following
boolean
de novo aml
Item
newly diagnosed de novo acute myeloid leukemia (aml)
boolean
C0023467 (UMLS CUI [1,1])
C1515568 (UMLS CUI [1,2])
secondary AML
Item
aml secondary to myelodysplastic syndromes (mds)
boolean
C0280449 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
secondary aml to leukemogenic therapy
Item
aml secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years
boolean
C0280449 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C2983796 (UMLS CUI [2,2])
bone marrow blasts
Item
bone marrow blasts >30%
boolean
C1982687 (UMLS CUI [1])
age
Item
age ≥ 65 years
boolean
C0001779 (UMLS CUI [1])
ECOG
Item
easter cooperative oncology group (ecog) 0-2
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
prior therapy for aml
Item
previous cytotoxic or biologic treatment for aml (except hydroxyurea)
boolean
C0023467 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C0020402 (UMLS CUI [2])
previous treatment with azacitidine, decitabine or cytarabine
Item
previous treatment with azacitidine, decitabine or cytarabine
boolean
C0004475 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C0049065 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0010711 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
prior use of targeted therapy agents
Item
prior use of targeted therapy agents (e.g., flt3 inhibitors, other kinase inhibitors)
boolean
C2985566 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
AML m3
Item
aml french american british subtype (fab m3)
boolean
C0023487 (UMLS CUI [1])
aml cytogenetics
Item
aml associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes
boolean
C0023467 (UMLS CUI [1,1])
C0008625 (UMLS CUI [1,2])
prior bone marrow or stem cell transplantation
Item
prior bone marrow or stem cell transplantation
boolean
C0005961 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C1504389 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
candidate for allogeneic bone marrow or stem cell transplant
Item
candidate for allogeneic bone marrow or stem cell transplant
boolean
C0005961 (UMLS CUI [1])
C1504389 (UMLS CUI [2])
malignant disease
Item
diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, "in-situ" carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure)
boolean
C0006826 (UMLS CUI [1])
malignant neoplasm of the liver
Item
malignant hepatic tumors
boolean
C0345904 (UMLS CUI [1])
uncontrolled systemic infection
Item
uncontrolled systemic infection
boolean
C3646020 (UMLS CUI [1])
hiv, hepatitis b or c
Item
active viral infection with human immunodeficiency virus (hiv) or hepatitis type b or c
boolean
C0019682 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
experimental drug use
Item
use of any experimental drug or therapy within 28 days prior to day 1
boolean
C0304229 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video